CMMB - Chemomab Therapeutics Revenue Dynamics YoY (Last Twelve Months)

Chemomab Therapeutics production capacities are fully utilized for current clinical trials. The trailing 12-month revenue trend on GURU.Markets reflects market expectations, where 0.00 indicates the level of this metric. Chemomab Therapeutics relies on the development of anti-inflammatory antibodies while ensuring a strict temperature-controlled delivery regime for patient safety.
Chemomab Therapeutics Ltd (CMMB) - metric breakdowns and financial figures

The unique CCL24 protein blocking mechanism provides Chemomab Therapeutics (CMMB) with significant pricing power in the fibrosis treatment segment. This market position directly determines the dynamics of the last twelve months (LTM) revenue growth rate. This indicator measures the speed of sales growth over a rolling year, identifying the business's stage of maturity. Stabilizing values signal a transition from expansion to sustainability. Analysis of this chart allows for an assessment of the asset's investment attractiveness.